Clinical Trials Directory

Trials / Completed

CompletedNCT03845387

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
74 (actual)
Sponsor
Kissei Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
20 Years – 79 Years
Healthy volunteers
Not accepted

Summary

Objective of this study is to investigate the efficacy, safety and pharmacokinetics of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.

Conditions

Interventions

TypeNameDescription
DRUGKDT-3594oral administration, dose titration
DRUGPramipexoleER formulation, oral administration, dose titration

Timeline

Start date
2019-02-26
Primary completion
2020-02-21
Completion
2020-02-21
First posted
2019-02-19
Last updated
2021-02-17

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT03845387. Inclusion in this directory is not an endorsement.